Table of contents
- Trial overview
- Who is being studied
- What the trials measure
- Trial phases and status
- What these studies mean for patients
Trial overview
The listed studies of 18F-Psma-1007 all focus on prostate cancer and use it in imaging-based research, mainly with PET/CT scanning.[1][2][3][4]
One trial compares PSMA-PET/CT with current guideline imaging for primary staging, another looks at cost-effectiveness and treatment selection, a third compares scan findings with histopathology, and a fourth studies treatment outcomes in oligo-metastatic hormone-sensitive disease.[1][2][3][4]
Who is being studied
The target population is men with prostate cancer, but the exact group changes from study to study.[1][2][3][4]
Newly diagnosed patients are included in the study that checks pelvic lymph node invasion before surgery.[2]
High-risk prostate cancer patients are included in the trial that compares PSMA-PET and mpMRI with tissue findings.[3]
Oligo-metastatic hormone-sensitive patients are included in the study that looks at outcomes after PSMA-based treatment versus standard care.[4]
Another study includes patients being staged for possible lymph node spread at the start of treatment.[1]
What the trials measure
The main goal in these trials is to see how well 18F-Psma-1007 helps find cancer and guide care.[1][2][3][4]
One primary outcome is the proportion of subjects with local lymph node metastases, which means cancer spread to nearby lymph nodes.[1]
Another study measures biochemical recurrence within two years after surgery, defined as PSA higher than 0.2 ng/ml.[2]
The high-risk prostate cancer study checks whether scan findings match histopathology, meaning tissue examined under a microscope.[3]
The metastatic study measures the fraction of patients with disease progression within 6 months and the time to progression.[4]
The cost-effectiveness study also looks at whether PSMA-PET/CT can reduce the need for extended pelvic lymph node dissection and lower overall healthcare costs.[2]
Trial phases and status
The trials include different development stages, which helps show how the research is being used in practice.[1][2][3][4]
Phase 4: one authorised study in primary prostate cancer staging with 320 planned participants.[1]
Phase 3: one authorised study in high-risk prostate cancer with 20 planned participants.[3]
Phase 2: one completed study in oligo-metastatic hormone-sensitive prostate cancer with 58 participants.[4]
Low intervention: one authorised study with 742 planned participants that focuses on cost-effectiveness and treatment selection.[2]
What these studies mean for patients
These trials are not mainly testing 18F-Psma-1007 as a treatment; they are testing how useful it is as an imaging tool in prostate cancer care.[1][2][3][4]
For patients, this kind of research may help doctors find disease spread earlier, choose the right treatment path, and avoid procedures that may not be needed.[2][3]
Across the listed trials, the main questions are whether 18F-Psma-1007 improves detection, matches tissue results, supports better treatment decisions, and helps measure outcomes more accurately.[1][2][3][4]
